Merck
CN
  • 'Designer drugs': update on the management of novel psychoactive substance misuse in the acute care setting.

'Designer drugs': update on the management of novel psychoactive substance misuse in the acute care setting.

Clinical medicine (London, England) (2014-08-08)
Christopher D Smith, Stefanie Robert
ABSTRACT

The use of novel psychoactive substances ('legal highs' or 'designer drugs') is increasing worldwide. Patients misusing such substances have been reported to experience severe or prolonged side effects requiring admission to acute or critical care wards. These complications can be life threatening if misdiagnosed or mismanaged. As physicians have traditionally had less involvement with the management of such patients compared with their colleagues in emergency departments an update in the management of such patients is indicated. Here we present a summary of the management of those novel substances with the potential for serious complications based on a review of current literature.

MATERIALS
Product Number
Brand
Product Description

Piperazine hydrate, European Pharmacopoeia (EP) Reference Standard
Supelco
Piperazine hexahydrate, analytical standard
Sigma-Aldrich
Piperazine, BioUltra, anhydrous, ≥99.0% (T)
Sigma-Aldrich
Piperazine, ReagentPlus®, 99%